Thank you very much.
I have a quick question for Medtronic. I read in your May company report that you had a 26% decrease in your first-quarter revenue due to COVID-19. Apparently the cardiac and vascular group saw the steepest decline, at 34%. We know that many procedures are being deferred right now in order to ensure that our health care system is not overwhelmed. Your falling revenue number suggests quite a high rate. What do you think that will cost in Canadian health outcomes?